Balaxi Pharmaceuticals Limited reported earnings results for the fourth quarter and full year ended March 31, 2022. For the fourth quarter, the company reported sales was INR 890.99 million compared to INR 529.53 million a year ago. Revenue was INR 931.66 million compared to INR 526.7 million a year ago. Net income was INR 127.11 million compared to INR 83.61 million a year ago. Basic earnings per share from continuing operations was INR 12.71 compared to INR 8.36 a year ago. Diluted earnings per share from continuing operations was INR 12.71 compared to INR 8.36 a year ago.
For the full year, sales was INR 2,793.88 million compared to INR 2,313.33 million a year ago. Revenue was INR 2,843.6 million compared to INR 2,335.61 million a year ago. Net income was INR 476.58 million compared to INR 381.37 million a year ago. Basic earnings per share from continuing operations was INR 47.66 compared to INR 38.14 a year ago. Diluted earnings per share from continuing operations was INR 47.66 compared to INR 38.14 a year ago.